Insmed Inc (INSM)vsMoonLake Immunotherapeutics (MLTX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MLTX
MoonLake Immunotherapeutics
$18.02
+7.84%
HEALTHCARE · Cap: $1.21B
Smart Verdict
WallStSmart Research — data-driven comparison
MLTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MLTX
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MLTX
MLTX has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while MLTX is a value play — different risk/reward profiles.
MLTX carries more volatility with a beta of 1.24 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
MLTX generates stronger free cash flow (-59M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on developing innovative therapies for chronic inflammatory diseases using its proprietary drug delivery platform. The firm is currently advancing its lead product candidate, a novel interleukin-17 inhibitor, through clinical trials, aiming to provide transformative treatment solutions that could significantly enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake is well-positioned to impact the immunotherapy market, addressing critical unmet medical needs while creating substantial value for shareholders.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?